Trial Profile
A Phase 2, Single Arm, European Multi-center Trial Evaluating the Efficacy of Afatinib as First-line or Later-line Treatment in Advanced Chordoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Chordoma
- Focus Therapeutic Use
- 19 Apr 2022 Planned End Date changed from 31 Dec 2021 to 1 Oct 2023.
- 19 Apr 2022 Planned primary completion date changed from 31 Dec 2021 to 1 Jul 2023.
- 19 Apr 2022 Status changed from recruiting to active, no longer recruiting.